Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.24.1
Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
director
vendor
segment
employee
consultant
shares
Dec. 31, 2022
USD ($)
shares
Accounting Policies [Line Items]      
Restricted cash $ 4,267 $ 4,267 $ 49,260
Tangible asset impairment   0  
In-Process R&D Impairment   1,904,314 0
Business combination, finite-lived intangibles 8,700,000 $ 8,700,000 10,600,000
Business segment | segment   1  
Geographic segments | segment   3  
Deferred tax liabilities, net 779,440 $ 779,440 689,121
Unrecognized uncertain income tax 0 0 0
Tax receivable $ 1,900,000 $ 1,900,000 $ 1,300,000
Unvested restricted common stock (in shares) | shares 229,373 229,373 30,000
Related party transactions, number of vendors | vendor   1  
Related party transactions, number of employees | employee   3  
Related party transactions, number of consultants | consultant   15  
In-process R&D, fair value $ 8,700,000 $ 8,700,000 $ 10,600,000
Consultant advisory services      
Accounting Policies [Line Items]      
Expenses from transactions with related party   500,000  
Employment related costs      
Accounting Policies [Line Items]      
Expenses from transactions with related party 100,000    
Ora, Inc | Clinical study services      
Accounting Policies [Line Items]      
Expenses from transactions with related party   $ 100,000  
Related party transactions, number of directors | director   1  
Bayon | Milestone payments to former shareholders      
Accounting Policies [Line Items]      
Expenses from transactions with related party $ 500,000    
Minimum      
Accounting Policies [Line Items]      
Estimated useful life (Years) 2 years 2 years  
Maximum      
Accounting Policies [Line Items]      
Estimated useful life (Years) 5 years 5 years